Presentations by Event

Presented at 2017 ACS Meeting, San Francisco, CA, April 2017

Discovery of ETX2514, a novel, rationally designed inhibitor of Class A, C and D β–lactamases, for the treatment of Gram-negative infections

Thomas Durand-Reville, ACS 2017

Program(s): etx2514